A comparison of UK and US guidelines for drug treatment in borderline personality disorder

References

• Abraham, P.F. & Calabrese, J.R. (2008). Evidenced-based pharmacologic treatment of borderline personality disorder: A shift from SSRIs to anticonvulsants and atypical antipsychotics? Journal of Affective Disorders, 111, 21–30.
   PubMed Web of Science ®Google Scholar
• Adil, J. (2010). Antipsychotics and borderline personality disorder. British Journal of Psychiatry, 196, 332.
   PubMedGoogle Scholar
• Adityanjee, Romine, A., Brown, E., Thuras, P., Lee, S. & Schulz, S.C. (2008). Quetiapine in patients with borderline personality disorder: An open-label trial. Annals of Clinical Psychiatry, 20, 219–226.
   PubMed Web of Science ®Google Scholar
• APA (2001). Practice guideline for the treatment of patients with borderline personality disorder. American Journal of Psychiatry, 158S10, 1–52.
   Google Scholar
• Bateman, A.W. & Fonagy, P. (1999). The effectiveness of partial hospitalization in the treatment of borderline personality disorder – a randomized controlled trial. American Journal of Psychiatry, 156, 1563–1569.
   PubMed Web of Science ®Google Scholar
• Bateman, A.W. & Fonagy, P. (2008). 8-year follow-up of patients treated for borderline personality disorder: Mentalization-based treatment versus treatment as usual. American Journal of Psychiatry, 165, 631–638.
   PubMed Web of Science ®Google Scholar
• Blum, N., St John, D., Pfohl, B., Stuart, S., McCormick, B., Allen, J., …Black, D.W. (2008). Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: A randomized controlled trial and 1-year follow-up. American Journal of Psychiatry, 165, 468–478.
   PubMed Web of Science ®Google Scholar
• Chanen, A.M., Jackson, H.J., McCutcheon, L.K., Jovev, M., Dudgeon, P., Yuen, H.P., …McGorry, P.D. (2008). Early intervention for adolescents with borderline personality disorder using cognitive analytic therapy: Randomised controlled trial. British Journal of Psychiatry, 193, 477–484.
   PubMed Web of Science ®Google Scholar
• Clarkin, J.F., Levy, K.N., Lenzenweger, M.F. & Kernberg, O.F. (2007). Evaluating three treatments for borderline personality disorder: A multiwave study. American Journal of Psychiatry, 164, 922–928.
   PubMed Web of Science ®Google Scholar
• Cowdry, R.W. & Gardner, D.L. (1988). Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of General Psychiatry, 45, 111–119.
   PubMed Web of Science ®Google Scholar
• Davidson, K., Norrie, J., Tyrer, P., Gumley, A., Tata, P., Murray, H. & Palmer, S. (2006). The effectiveness of cognitive behavior therapy for borderline personality disorder: Results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders, 20, 450–465.
   PubMed Web of Science ®Google Scholar
• Davidson, K.M., Tyrer, P., Norrie, J., Palmer. S.J. & Tyrer, H. (2010). Cognitive therapy v. usual treatment for borderline personality disorder: Prospective 6-year follow-up. British Journal of Psychiatry, 197, 456–462.
   PubMed Web of Science ®Google Scholar
• de la Fuente, J.M. & Lotstra, F. (1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology, 4, 479–486.
   PubMed Web of Science ®Google Scholar
• Eli Lilly (2007). Efficacy and safety of olanzapine in patients with borderline personality disorder: A randomized double-blind comparison with placebo. (Summary 6253, Clinical Study Summary: Study F1D-MC-HGKK). Available at: http://www.clinicalstudyresults.org.documents/company-study_2339_0.pdf (accessed 22 June 2011).
   Google Scholar
• Gaebel, W., Weinmann, S., Sartorius, N., Rutz, W. & McIntyre, J.S. (2005). Schizophrenia practice guidelines: International survey and comparison. British Journal of Psychiatry, 187, 248–255.
   PubMed Web of Science ®Google Scholar
• Giesen-Bloo, J., van Dyck, R., Spinhoven, P., van Tilburg, W., Dirksen, C., van Asselt, T., …Arntz, A. (2006). Outpatient psychotherapy for borderline personality disorder: Randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry, 63, 649–658.
   PubMed Web of Science ®Google Scholar
• Goldberg, S.C., Schulz, S.C., Schulz, P.M., Resnick, R.J., Hamer, R.M. & Friedel, R.O. (1986). Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Archives of General Psychiatry, 43, 680–686.
   PubMed Web of Science ®Google Scholar
• Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., … GRADE Working Group (2008). GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. British Medical Journal, 336, 924–926.
   PubMed Web of Science ®Google Scholar
• Kendall, T., Burbeck, R. & Bateman, A. (2010). Pharmacotherapy for borderline personality disorder: NICE guideline. British Journal of Psychiatry, 196, 158–159.
   PubMed Web of Science ®Google Scholar
• Lieb, K., Völlm, B., Rücker, G., Timmer, A. & Stoffers, J.M. (2010). Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. British Journal of Psychiatry, 196, 4–12.
   PubMed Web of Science ®Google Scholar
• Linehan, M.M., Armstrong, H.E., Suarez, A., Allmon, D. & Heard, H.L. (1991). Cognitive behavioural treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry, 48, 1060–1064.
   PubMed Web of Science ®Google Scholar
• Montgomery, S.A. & Montgomery, D. (1982) Pharmacological prevention of suicidal behavior. Journal of Affective Disorders, 4, 291–298.
   PubMed Web of Science ®Google Scholar
• Mulder, R. (2009). Is borderline personality really a personality disorder? Personality and Mental Health, 3, 85.
   Google Scholar
• NCCMH (2009). Borderline Personality Disorder: Treatment and management. Leicester & London: British Psychological Society & Royal College of Psychiatrists.
   Google Scholar
• Newton-Howes, G. & Tyrer, P. (2003). Pharmacotherapy for personality disorders. Expert Opinion in Pharmacotherapy, 4, 1643–1649.
   PubMed Web of Science ®Google Scholar
• NICE (2009) Borderline Personality Disorder: Treatment and Management. NICE clinical guideline 78. London: NICE. Available from www.nice.org.uk/CG78 (accessed 3 March 2011).
   Google Scholar
• Paris, J., Silk, K.R., Gunderson, J., Links, P.S. & Zanarini, M. (2009). The case for retaining borderline personality disorder as a psychiatric diagnosis. Personality and Mental Health, 3, 96–100
   Google Scholar
• Paton, C. (2008). Prescribing in pregnancy. British Journal of Psychiatry, 192, 321–322.
   PubMedGoogle Scholar
• Pope, A., Adams, A., Paton, C., Weaver, T. & Barnes, T.R.E. (2010). Assessment of adverse effects in clinical studies of antipsychotic medication: Survey of methods. British Journal of Psychiatry, 197, 67–72.
   PubMedGoogle Scholar
• Rinne, T., van den Brink, W., Wouters, L. & van Dyck, R. (2002). SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry, 159, 2048–2054.
   PubMed Web of Science ®Google Scholar
• Salzman, C., Wolfson, A.N., Schatzberg, A., Looper, J., Henke, R., Albanese, M., …Miyawaki, E. (1995). Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology, 15, 23–29.
   PubMed Web of Science ®Google Scholar
• Sanislow, C.A., Little, T.D., Ansell, E.B., Grilo, C.M., Daversa, M., Markowitz, J.C., …McGlashan, T.H. (2009). Ten-year stability and latent structure of the DSM-IV schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. Journal of Abnormal Psychology, 118, 507–519.
   PubMedGoogle Scholar
• Saunders, E.F.H. & Silk, K.R. (2009). Personality trait dimensions and the pharmacologic treatment of borderline personality disorder. Journal of Clinical Psychopharmacology, 29, 461–467.
   PubMed Web of Science ®Google Scholar
• Schulz, S.C., Zanarini, M.C., Bateman, A., Bohus, M., Detke, H.C., Trzaskoma, Q., …Corya, S. (2008). Olanzapine for the treatment of borderline personality disorder: Variable dose 12-week randomised double-blind placebo-controlled study. British Journal of Psychiatry, 193, 485–492.
   PubMed Web of Science ®Google Scholar
• Siever, L.J. & Davis, K.L. (1991). A psychobiological perspective on the personality disorders. American Journal of Psychiatry, 148, 1647–1658.
   PubMed Web of Science ®Google Scholar
• Soloff, P.H. (1998). Algorithms for pharmacological treatment of personality dimensions: Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bulletin of the Menninger Clinic, 62, 195–214.
   PubMed Web of Science ®Google Scholar
• Soloff, P.H., Cornelius, J., George, A., Nathan, S., Perel, J.M. & Ulrich, R.F. (1993). Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry, 50, 377–385.
   PubMed Web of Science ®Google Scholar
• Soloff, P.H., George, A., Nathan, R.S., Schulz, P.M., Cornelius, J.R., Herring, J. & Perel, J.M. (1989). Amitriptyline versus haloperidol in borderlines: Final outcomes and predictors of response. Journal of Clinical Psychopharmacology, 9, 238–246.
   PubMedGoogle Scholar
• Tyrer, P. (2009). Why borderline personality disorder is neither borderline nor a personality disorder. Personality and Mental Health, 3, 86–95.
   Web of Science ®Google Scholar
• Yang, M., Coid, J. & Tyrer, P. (2010). Personality pathology recorded by severity: National survey. British Journal of Psychiatry, 197, 193–199.
   PubMed Web of Science ®Google Scholar